SCHEMBL4899705

SCHEMBL4899705

CCn1nc(-c2ccccc2)c(C(C)=O)c(Nc2cccc(Cl)c2C)c1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.63
HTR1A P08908 2/20 0.44
ADRA1A P35348 2/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1B P35368 1/20 0.44
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
MT-CO2 P00403 1/20 0.42
LMNA P02545 1/20 0.42
TTR P02766 1/20 0.42
PLA2G1B P04054 1/20 0.42
CYP1A2 P05177 1/20 0.42
PGR P06401 1/20 0.42
CYP3A4 P08684 1/20 0.42
ADRA2A P08913 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
AR P10275 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4707277 0.92 PDE4B (0.67) PDE4BHTR1AADRA1AADRA1DADRA1B
SCHEMBL4708530 0.91 PDE4B (0.64) PDE4BHTR1AADRA1AADRA1DADRA1B
SCHEMBL4706076 0.90 PDE4B (0.65) PDE4BTP53SMN1; SMN2LMNAACHE
SCHEMBL4706081 0.89 PDE4B (0.69) PDE4BHTR1AADRA1AADRA1DADRA1B
SCHEMBL4707441 0.88 PDE4B (0.63) PDE4BHTR1AADRA1AADRA1DADRA1B
SCHEMBL4707018 0.87 PDE4B (0.64) PDE4BHTR1AADRA1AADRA1DADRA1B
SCHEMBL6170267 0.87 PDE4B (0.59) PDE4BHTR1AADRA1AADRA1DADRA1B
SCHEMBL4705603 0.86 PDE4B (0.69) PDE4BTP53SMN1; SMN2LMNAACHE
SCHEMBL4706948 0.85 PDE4B (0.56) PDE4BHTR1AADRA1AADRA1DADRA1B
SCHEMBL4708171 0.85 PDE4B (0.64) PDE4BHTR1AADRA1AADRA1DADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed
EP-1503992-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2005-02-09 EP disclosed
WO-2003097613-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS ALMIRALL PRODESFARMA SA (ES) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885HTR1A 1051/4885ADRA1A 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.